Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Once a woman turns 40, experts advise that she at the very least think about starting a breast cancer screening program. According to a recent study, Black women need this advice above all others.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
2.
Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.
3.
Black and Hispanic children with high-risk neuroblastoma have worse outcomes despite standardized treatment
4.
The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.
5.
Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care
1.
Metabolic Symbiosis Within the Tumor Niche: Mechanisms, Clinical Implications, and Therapeutic Opportunities
2.
The Mysterious World of Petechiae: Exploring Causes and Treatments
3.
Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer
4.
Don't Ignore Your Vision Loss: What You Need to Know About Amaurosis Fugax
5.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
Navigating the Complexities of Ph Negative ALL - Part VII
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge